{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:42:56Z","timestamp":1771267376991,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.thromres.2014.10.015","type":"journal-article","created":{"date-parts":[[2014,10,22]],"date-time":"2014-10-22T19:59:42Z","timestamp":1414007982000},"page":"5-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Fever as a Risk Factor for Increased Response to Vitamin K Antagonists: A Review of the Evidence and Potential Mechanisms"],"prefix":"10.1016","volume":"135","author":[{"given":"Timothy H.","family":"Self","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie S.","family":"Oliphant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne B.","family":"Reaves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy M.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher W.","family":"Sands","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2 Suppl.","key":"10.1016\/j.thromres.2014.10.015_bb0005","doi-asserted-by":"crossref","first-page":"e44s","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2014.10.015_bb0010","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1097\/00007611-198912000-00035","article-title":"Effect of hypothyroidism on warfarin anticoagulation","volume":"82","author":"Stephens","year":"1989","journal-title":"South Med J"},{"key":"10.1016\/j.thromres.2014.10.015_bb0015","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/jama.1975.03240230039019","article-title":"Warfarin-induced hypoprothrombinemia: potentiation by hyperthyroidism","volume":"231","author":"Self","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2014.10.015_bb0020","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11239-012-0811-x","article-title":"Comparison of initial warfarin response in obese patients versus non-obese patients","volume":"36","author":"Wallace","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.thromres.2014.10.015_bb0025","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1185\/030079906X132479","article-title":"Does heart failure exacerbation increase response to warfarin? A critical review of the literature","volume":"22","author":"Self","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.thromres.2014.10.015_bb0030","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1053\/j.ajkd.2010.05.023","article-title":"Warfarin dosing in patients with impaired kidney function","volume":"56","author":"Limdi","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.thromres.2014.10.015_bb0035","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/phar.1445","article-title":"The effect of chronic kidney disease on warfarin dosing requirements","volume":"34","author":"Sakaan","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"2518","key":"10.1016\/j.thromres.2014.10.015_bb0040","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1126\/science.97.2518.313","article-title":"Influence of fever upon the action of 3,3 methylene bis-(4-hydroxycoumarin) (dicumarol)","volume":"97","author":"Richards","year":"1943","journal-title":"Science"},{"key":"10.1016\/j.thromres.2014.10.015_bb0045","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1055\/s-0038-1654782","article-title":"The biological disappearance rate of prothrombin, Factors VII, IX, and X from plasma in hypothyroidism, hyperthyroidism, and during fever","volume":"10","author":"Loeliger","year":"1964","journal-title":"Thromb Diath Haemorrh"},{"key":"10.1016\/j.thromres.2014.10.015_bb0050","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jama.279.9.657","article-title":"Acetaminophen and other risk factors for excessive warfarin anticoagulation","volume":"279","author":"Hylek","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2014.10.015_bb0055","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1055\/s-0037-1616088","article-title":"Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation","volume":"86","author":"Penning-van Beest","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.10.015_bb0060","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/00001721-200212000-00010","article-title":"Levels of vitamin K-dependent procoagulant and anticoagulant proteins in over-anticoagulated patients","volume":"13","author":"Penning-van Beest","year":"2002","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.thromres.2014.10.015_bb0065","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1160\/TH08-04-0265","article-title":"Risk factors of vitamin K antagonist overanticoagulation: A case-control study in unselected patients referred to an emergency department","volume":"100","author":"Cadiou","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.10.015_bb0070","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2515\/therapie:2008058","article-title":"Factors of therapeutic imbalance of antivitamins K and their haemorrhagic consequences in elderly","volume":"63","author":"Chatap","year":"2008","journal-title":"Therapie"},{"key":"10.1016\/j.thromres.2014.10.015_bb0075","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jamainternmed.2013.13957","article-title":"Warfarin interactions with antibiotics in the ambulatory care setting","volume":"174","author":"Clark","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.thromres.2014.10.015_bb0080","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2125.1986.tb05190.x","article-title":"Stereoselective interaction between the R enantiomer of warfarin and cimetidine","volume":"21","author":"Choonara","year":"1986","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.thromres.2014.10.015_bb0085","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/clpt.1987.104","article-title":"Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects","volume":"42","author":"Toon","year":"1987","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.thromres.2014.10.015_bb0090","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1172\/JCI117582","article-title":"Endotoxin administration in humans inhibits hepatic P450-mediated drug metabolism","volume":"94","author":"Shedlofsky","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.thromres.2014.10.015_bb0095","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1046\/j.1365-2125.1997.00603.x","article-title":"Endotoxin depresses hepatic cytochrome P450-mediated drug metabolism in women","volume":"43","author":"Shedlofsky","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.thromres.2014.10.015_bb0100","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/clpt.1985.117","article-title":"Antipyrine clearance in pneumonia","volume":"37","author":"Sonne","year":"1985","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.thromres.2014.10.015_bb0105","first-page":"229","article-title":"Theophylline disposition in acutely ill hospitalized patients: the effect of smoking, heart failure, severe airway obstruction and pneumonia","volume":"118","author":"Powell","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.thromres.2014.10.015_bb0110","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S0140-6736(78)90305-7","article-title":"Altered theophylline pharmacokinetics during acute respiratory viral illness","volume":"1","author":"Chang","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2014.10.015_bb0115","first-page":"2480","article-title":"Differential effect of IFN alfa-2b on the cytochrome P450 enzyme system: A potential basis of IFN toxicity and its modulation by other drugs","volume":"8","author":"Islam","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.thromres.2014.10.015_bb0120","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/bmj.311.7000.292a","article-title":"Potentiation of warfarin by interferon","volume":"311","author":"Adachi","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2014.10.015_bb0125","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/jps.2600651127","article-title":"Effect of temperature on binding of warfarin by human serum albumin","volume":"65","author":"Oester","year":"1976","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.thromres.2014.10.015_bb0130","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/11595560-000000000-00000","article-title":"A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy","volume":"51","author":"Verstuyft","year":"2012","journal-title":"Clin Pharmacokinet"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814005714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814005714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T14:08:34Z","timestamp":1565964514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384814005714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0049384814005714"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2014.10.015","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fever as a Risk Factor for Increased Response to Vitamin K Antagonists: A Review of the Evidence and Potential Mechanisms","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2014.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}